[¹¹C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy
- PMID: 25697127
- DOI: 10.1007/s00259-015-3015-8
[¹¹C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy
Abstract
Purpose: Over the last decade, PET/CT with radiolabelled choline has been shown to be useful for restaging patients with prostate cancer (PCa) who develop biochemical failure. The limitations of most clinical studies have been poor validation of [(11)C]choline PET/CT-positive findings and lack of survival analysis. The aim of this study was to assess whether [(11)C]choline PET/CT can predict survival in hormone-naive PCa patients with biochemical failure.
Methods: This retrospective study included 302 hormone-naive PCa patients treated with radical prostatectomy who underwent [(11)C]choline PET/CT from 1 December 2004 to 31 July 2007 because of biochemical failure (prostate-specific antigen, PSA, >0.2 ng/mL). Median PSA was 1.02 ng/mL. PCa-specific survival was estimated using Kaplan-Meier curves. Cox regression analysis was used to evaluate the association between clinicopathological variables and PCa-specific survival. The coefficients of the covariates included in the Cox regression analysis were used to develop a novel nomogram.
Results: Median follow-up was 7.2 years (1.4 - 18.9 years). [(11)C]Choline PET/CT was positive in 101 of 302 patients (33%). Median PCa-specific survival after prostatectomy was 14.9 years (95% CI 9.7 - 20.1 years) in patients with positive [(11)C]choline PET/CT. Median survival was not achieved in patients with negative [(11)C]choline PET/CT. The 15-year PCa-specific survival probability was 42.4% (95% CI 31.7 - 53.1%) in patients with positive [(11)C]choline PET/CT and 95.5% (95% CI 93.5 - 97.5 %) in patients with negative [(11)C]choline PET/CT. In multivariate analysis, [(11)C]choline PET/CT (hazard ratio 6.36, 95% CI 2.14 - 18.94, P < 0.001) and Gleason score >7 (hazard ratio 3.11, 95% CI 1.11 - 8.66, P = 0.030) predicted PCa-specific survival. An internally validated nomogram predicted 15-year PCa-specific survival probability with an accuracy of 80%.
Conclusion: Positive [(11)C]choline PET/CT after biochemical failure predicts PCa-specific survival in hormone-naive PCa patients. Prospective studies are warranted to confirm our results before more extensive use of [(11)C]choline PET/CT for prognostic stratification of PCa patients.
Similar articles
-
11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.J Nucl Med. 2014 Feb;55(2):233-41. doi: 10.2967/jnumed.113.123380. Epub 2014 Jan 9. J Nucl Med. 2014. PMID: 24408897
-
11C-choline PET/CT predicts survival in prostate cancer patients with PSA < 1 NG/ml.Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):921-929. doi: 10.1007/s00259-018-4253-3. Epub 2019 Jan 10. Eur J Nucl Med Mol Imaging. 2019. PMID: 30631911
-
Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.Clin Nucl Med. 2012 Apr;37(4):325-31. doi: 10.1097/RLU.0b013e31823363b0. Clin Nucl Med. 2012. PMID: 22391699
-
The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.Eur Urol. 2011 Jan;59(1):51-60. doi: 10.1016/j.eururo.2010.09.004. Epub 2010 Sep 15. Eur Urol. 2011. PMID: 20869161 Review.
-
Rapidly changing landscape of PET/CT imaging in prostate cancer.Curr Opin Urol. 2016 Sep;26(5):493-500. doi: 10.1097/MOU.0000000000000309. Curr Opin Urol. 2016. PMID: 27467137 Review.
Cited by
-
Positron emission tomography in prostate cancer: An update on state of the art.Indian J Urol. 2018 Jul-Sep;34(3):172-179. doi: 10.4103/iju.IJU_320_17. Indian J Urol. 2018. PMID: 30034126 Free PMC article. Review.
-
Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy.Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1542-1550. doi: 10.1007/s00259-019-04308-5. Epub 2019 Mar 16. Eur J Nucl Med Mol Imaging. 2019. PMID: 30879122
-
Application of 18F-PSMA-1007 PET/MR Imaging in Early Biochemical Recurrence of Prostate Cancer: Results of a Prospective Study of 60 Patients with Very Low PSA Levels ≤ 0.5 ng/mL.Cancers (Basel). 2023 Aug 20;15(16):4185. doi: 10.3390/cancers15164185. Cancers (Basel). 2023. PMID: 37627213 Free PMC article.
-
Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1784-93. doi: 10.1007/s00259-015-3123-5. Epub 2015 Jul 21. Eur J Nucl Med Mol Imaging. 2015. PMID: 26194716
-
Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications.Adv Radiat Oncol. 2018 Sep 5;4(1):79-89. doi: 10.1016/j.adro.2018.08.022. eCollection 2019 Jan-Mar. Adv Radiat Oncol. 2018. PMID: 30706014 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous